Format

Send to

Choose Destination
Maturitas. 2003 Dec 10;46(4):295-9.

Cyclooxygenase-2 expression in the endometrium at the end of 2 years' continuous combined hormone replacement therapy.

Author information

1
Department of Obstetrics and Gynecology, Kaohsiung Municipal Hsiao Kang Hospital, Hsiao-Kang District, 812 Kaohsiung, Taiwan, ROC.

Abstract

OBJECTIVE:

To evaluate the change of endometrial histology and the expression of cyclooxygenase-2 (Cox-2) in the endometrium after continuous combined hormone replacement therapy (HRT).

METHODS:

Forty-five postmenopausal women were recruited. All participants received 0.625 mg conjugated equine estrogen (CEE) and 2.5 mg medroxyprogesterone (MPA) daily for 2 years. Endometrial biopsy was performed twice, before medication (baseline) and after 2 years of HRT, respectively. Immunohistochemistry was used to detect the presence of Cox-2 expression.

RESULTS:

More atrophic and weak secretory features of endometrium were noted after the 2-year HRT. Endometrial hyperplasia and carcinoma were not found and immunohistochemistry results revealed that Cox-2 was not expressed in the endometrium.

CONCLUSION:

Cox-2, known to play an important role in the tumorigenesis of cancer, was not stained in endometrium tissue after hormonal induction and more endometrium atrophy was noted after the 2-year HRT. From the results, it is noted that continuous combined HRT may be a relatively safe and appropriate regimen for long-term use in postmenopausal women.

PMID:
14625126
DOI:
10.1016/s0378-5122(03)00218-4
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center